KRT19 and ductal breast carcinoma in situ: In our study, we tested serum CK19-2G2 levels in four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients,eighty-one healthy controls and twenty-one breast benign disease patients.